The hardware and bandwidth for this mirror is donated by METANET, the Webhosting and Full Service-Cloud Provider.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]metanet.ch.

FBCRM: Phase I Optimal Dose Assignment using the FBCRM and MFBCRM Methods

Performs dose assignment and trial simulation for the FBCRM (Fully Bayesian Continual Reassessment Method) and MFBCRM (Mixture Fully Bayesian Continual Reassessment Method) phase I clinical trial designs. These trial designs extend the Continual Reassessment Method (CRM) and Bayesian Model Averaging Continual Reassessment Method (BMA-CRM) by allowing the prior toxicity skeleton itself to be random, with posterior distributions obtained from Markov Chain Monte Carlo. On average, the FBCRM and MFBCRM methods outperformed the CRM and BMA-CRM methods in terms of selecting an optimal dose level across thousands of randomly generated simulation scenarios. Details on the methods and results of this simulation study are available on request, and the manuscript is currently under review.

Version: 1.1
Imports: Rcpp (≥ 0.12.18)
LinkingTo: Rcpp, RcppArmadillo
Published: 2022-10-29
DOI: 10.32614/CRAN.package.FBCRM
Author: Soham Mahato [aut], Andrew G Chapple [aut, cre]
Maintainer: Andrew G Chapple <achapp at lsuhsc.edu>
License: GPL-2
NeedsCompilation: yes
CRAN checks: FBCRM results

Documentation:

Reference manual: FBCRM.pdf

Downloads:

Package source: FBCRM_1.1.tar.gz
Windows binaries: r-devel: FBCRM_1.1.zip, r-release: FBCRM_1.1.zip, r-oldrel: FBCRM_1.1.zip
macOS binaries: r-release (arm64): FBCRM_1.1.tgz, r-oldrel (arm64): FBCRM_1.1.tgz, r-release (x86_64): FBCRM_1.1.tgz, r-oldrel (x86_64): FBCRM_1.1.tgz

Linking:

Please use the canonical form https://CRAN.R-project.org/package=FBCRM to link to this page.

These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.